MedTrace Logo

A Study of NB003 in Patients With Advanced Malignancies

NCT04936178 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2025-12-22

No results posted yet for this study

Summary

This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

NB003 tablets

NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.

Sponsors & Collaborators

  • Ningbo Newbay Technology Development Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-06
Primary Completion
2025-08-01
Completion
2025-08-01
FDA Drug
Yes

Countries

  • United States
  • China
  • France
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04936178 on ClinicalTrials.gov